Amylyx Pharmaceuticals (AMLX) Operating Leases (2022 - 2026)

Amylyx Pharmaceuticals' Operating Leases history runs 5 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 1268.81% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $4.5 million, a 1268.81% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, up 914.69% from the prior year.
• Operating Leases declined to $4.5 million in Q1 2026 per AMLX's latest filing, from $4.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.8 million in Q1 2022 and bottomed at $327000.0 in Q1 2025.
• The 5-year median for Operating Leases is $4.2 million (2022), against an average of $3.5 million.
• Across the five-year window, Operating Leases slumped 76.62% in 2024 and surged 1268.81% in 2026, its largest moves.
• Year by year, Operating Leases stood at $4.2 million in 2022, then sank by 53.27% to $2.0 million in 2023, then sank by 76.62% to $463000.0 in 2024, then surged by 914.69% to $4.7 million in 2025, then decreased by 4.73% to $4.5 million in 2026.
• Per Business Quant, the three latest AMLX Operating Leases figures stand at $4.5 million (Q1 2026), $4.7 million (Q4 2025), and $5.0 million (Q3 2025).